Articles tagged with: Panobinostat
Headline, News »
Interim results from a Phase 2 study show that panobinostat may be clinically beneficial for certain multiple myeloma patients with advanced disease.
In the study, patients who had relapsed and were no longer responsive to Velcade-based treatments received panobinostat in combination with Velcade and dexamethasone.
Although the results generally are being viewed as favorable, “It is hard to interpret them because you don’t really know how the patients would have done with just Velcade and dexamethasone alone,” explained Dr. Leif Bergsagel, a myeloma specialist from the Mayo Clinic in Arizona,…
Headline, News »
As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma therapies.
The afternoon myeloma sessions were focused, in fact, on potential new therapies.
The Beacon’s previous ASH 2011 update covered the afternoon presentations about carfilzomib and pomalidomide, two potential myeloma therapies that are in the late stages of development.
This update covers the afternoon’s presentations about four other potential new myeloma therapies —…
Featured, Headline, News »
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts’ thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology — which undoubtedly will host discussions of many potential new myeloma treatments — it seems an appropriate time to go back to the…
News »
MDX-1097 Receives Orphan Drug Status For Multiple Myeloma – The Australian bio-therapeutic company Immune System Therapeutics announced last week that it has received orphan drug designation from the United States Food and Drug Administration (FDA) for its investigational drug MDX-1097. MDX-1097 is an antibody that binds to certain proteins on the surface of myeloma cells, triggering the immune system to kill the cancer cells. The FDA uses the orphan drug designation to promote the development of new treatments for rare diseases that affect fewer than 200,000 individuals in the United States. The orphan drug status provides the developer of the drug with multiple benefits, including funding for clinical trials, accelerated FDA approval, and marketing exclusivity for up to seven years. For more information, please see the Immune System Therapeutics press release.
MD Anderson Cancer Center Announces Start Of Phase 1 Trial With Carfilzomib Plus Panobinostat In Myeloma – The MD Anderson Cancer Center announced last week that it will be starting a Phase 1 trial in early August to determine the highest tolerable dose levels of carfilzomib in combination with panobinostat in relapsed and refractory multiple myeloma patients. The safety of the combination treatment will also be assessed. Carfilzomib, which belongs to the same class of drugs as Velcade (bortezomib), is a new drug from Onyx Pharmaceuticals that is currently being investigated as a potential treatment for multiple myeloma. Panobinostat is an oral experimental cancer drug that is being developed by Novartis. For more information, please see the clinical trial description.
Music Against Myeloma – On Wednesday, July 13, several bands will play at Greenhouse in Manhattan to raise awareness and funds for multiple myeloma. The event starts at 8 p.m. and will feature live bands, drink specials, cupcakes, and more. All proceeds will go to the International Myeloma Foundation. For more information and tickets, please see the Music Against Myeloma website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
Headline, News »
Monday was the fourth day of the American Society of Clinical Oncology (ASCO 2011) annual meeting in Chicago. Although the meeting concluded yesterday, Monday was the last day of the meeting that contained any myeloma-relevant material.
The morning started with a session recapping highlights of the meeting from Sunday. Dr. Ivan Borello from the Johns Hopkins University School of Medicine was invited to give a 15-minute presentation recapping the myeloma highlights (see Part 1 and Part 2 of The Beacon’s Day Three update for more information).
The rest…
